Washington Capital Management’s GSK GSK Stock Holding History

Washington Capital Management’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-17,137	Closed	-$735K	–	105
2024 Q1	$735K	Sell	17,137 -32	-0.2%	-$1.32K	0.6%	43
2023 Q4	$636K	Sell	17,169 -1,728	-9%	-$62K	0.54%	49
2023 Q3	$685K	Hold	18,897	–	–	0.63%	43
2023 Q2	$673K	Hold	18,897	–	–	0.57%	44
2023 Q1	$672K	Sell	18,897 -380	-2%	-$13.3K	0.6%	39
2022 Q4	$677K	Sell	19,277 -592	-3%	-$19.7K	0.62%	40
2022 Q3	$585K	Buy	19,869 +4,749	+31%	+$180K	0.59%	46
2022 Q2	$823K	Buy	15,120 +10,140	+204%	+$560K	0.79%	36
2022 Q1	$271K	Sell	4,980 -200	-4%	-$10.9K	0.22%	100
2021 Q4	$286K	Sell	5,180 -356	-6%	-$18.5K	0.23%	99
2021 Q3	$264K	Sell	5,536 -488	-8%	-$24.5K	0.23%	101
2021 Q2	$300K	Hold	6,024	–	–	0.36%	96
2021 Q1	$269K	Buy	6,024 +972	+19%	+$44.1K	0.25%	99
2020 Q4	$232K	Buy	+5,052	New	+$232K	0.22%	99

Other funds holding GSK

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.2B AUM 37.55% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return

Washington Capital Management's GSK Position: Q2 2024 in Review

Washington Capital Management sold out of GSK (GSK) in Q2 2024, closing a stake of 17,137 shares — an estimated $735K sold.

Washington Capital Management first reported a position in GSK in Q4 2020 and held it in 14 quarters. The position peaked at $823K in Q2 2022. 885 funds tracked by Wall St. Rank hold GSK as of Q2 2024.

Washington Capital Management reported no remaining GSK position as of Q2 2024 after selling out during the quarter.
Washington Capital Management sold 17,137 GSK shares in Q2 2024, an estimated $735K.
Washington Capital Management first reported a position in GSK in Q4 2020 and held it in 14 quarters.
Washington Capital Management's GSK position peaked at $823K in Q2 2022.
885 funds tracked by Wall St. Rank held GSK as of Q2 2024.

Based on Washington Capital Management's 13F filing for Q2 2024, filed 19 Jul 2024.